A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Mirogabalin (Primary)
- Indications Fibromyalgia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 12 Jul 2017 Status changed from active, no longer recruiting to completed.
- 29 Jun 2017 Planned End Date changed from 1 Jul 2017 to 6 Jul 2017.
- 29 Jun 2017 Planned primary completion date changed from 1 Jul 2017 to 6 Jul 2017.